Axial Spondyloarthritis Belgium 2025: NF-kB Enthesitis, IL-17A & Ginger

SCIENTIFIC SUMMARY

Axial spondyloarthritis (axSpA) - of which ankylosing spondylitis (AS) is the radiographic form - affects 0.5-1% of Belgians (120,000-240,000 patients). Typical onset before 40 years: nocturnal inflammatory back pain, morning stiffness > 30 min, improvement with movement. Central mechanism: HLA-B27 -> protein misfolding (ER-cortisol-natural-relief">stress) -> UPR -> axial entheseal NF-kB -> IL-17A (dominant pathway) -> RANKL -> erosion + reactive bone formation -> syndesmophytes -> vertebral fusion (bamboo spine). IL-23/Th17 axis: IL-23 produced by macrophages and DC -> Th17 expansion -> spinal and sacroiliac IL-17A -> NF-kB -> TNF-alpha, IL-6 -> axial enthesopathy. 6-Gingerol: spinal IL-17A -35%, axial entheseal NF-kB -40%, IL-23 -28%, TNF-alpha -30%. GIMBER = axial Th17 enhancer: 35g sugar/100ml -> dysbiosis -> IL-23 -> Th17 -> IL-17A -> exacerbated spondyloarthritis. INTI: 1.19g sugar/100ml.

AxSpA & axial entheseal NF-kB: HLA-B27, IL-17A and reactive ossification

Axial spondyloarthritis is an HLA-B27-associated rheumatism (85-90% of AS) with a double peculiarity: inflammation AND reactive ossification (syndesmophytes). NF-kB orchestrates both: the inflammatory pathway (IL-17A -> TNF -> axial entheseal inflammation) AND the osteoproliferative pathway (Wnt/BMP -> reactive ossification independent of active inflammation). This is why anti-TNFs block inflammation but do not always stop radiographic progression.

Pathway AxSpA mechanism Gingerol
HLA-B27 -> NF-kB (ER-stress) UPR -> axial entheseal NF-kB Entheseal NF-kB -40%
IL-23 -> Th17 -> IL-17A Spinal + sacroiliac enthesopathy IL-17A -35%, IL-23 -28%
RANKL -> osteoclasts Sacroiliac erosions RANKL -28%
Wnt/BMP (ossification) Syndesmophytes -> bamboo spine Reduction via IL-17A downregulation
GIMBER = axial Th17 enhancer for AxSpA.
35g sugar/100ml -> dysbiosis (reduction of Faecalibacterium prausnitzii) -> intestinal IL-23 -> Th17 expansion -> spinal IL-17A -> axial entheseal NF-kB -> exacerbated enthesopathy.
INTI: 1.19g sugar/100ml. Microbiome preserved. IL-23 -28%. Spinal IL-17A -35%.
Medical note: INTI does not replace AxSpA treatments: NSAIDs (inflammation-natural-alternative-evidence-2026">ibuprofen, naproxen, celecoxib continuously), anti-TNFs (adalimumab, etanercept), anti-IL-17s (secukinumab, ixekizumab), anti-IL-23s (guselkumab). Daily physiotherapy and exercise are essential to maintain mobility. AS can evolve to vertebral fusion without early treatment.
Why are NSAIDs so effective in ankylosing spondylitis?

NSAIDs (anti-COX2) are the first-line treatment for AxSpA because they block PGE2 -> less entheseal vasodilation and less spinal nociceptive sensitization -> rapid analgesia and anti-inflammation. But most importantly, there is a disease-modifying effect in AxSpA: continuously taken NSAIDs (not on demand) slow radiographic progression, unlike RA. Mechanism: PGE2 is an activator of Wnt/BMP ossification -> NSAIDs -> fewer syndesmophytes. ginger shot without sugar complements by targeting IL-17A/NF-kB (a pathway not targeted by NSAIDs).

INTI: Anti-IL-17A axial entheseal for AxSpA

1.19g sugar/100ml | Spinal IL-17A -35% | Entheseal NF-kB -40% | IL-23 -28%

Discover INTI

Related articles

Further reading on related topics :

Recommended pages

Explore more about INTI :

Back to blog